Pfizer Inc. (NYSE:PFE) Shares Sold by Desjardins Global Asset Management Inc.

Desjardins Global Asset Management Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 27.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 36,750 shares of the biopharmaceutical company’s stock after selling 13,744 shares during the period. Desjardins Global Asset Management Inc.’s holdings in Pfizer were worth $1,058,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. RB Capital Management LLC grew its position in Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. lifted its stake in shares of Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after acquiring an additional 400 shares during the period. United Bank lifted its holdings in shares of Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after buying an additional 290 shares during the period. Ergoteles LLC boosted its stake in Pfizer by 136.3% during the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after buying an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp raised its position in Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after acquiring an additional 79,887 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PFE shares. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Trading Down 1.1 %

Shares of NYSE:PFE opened at $25.41 on Thursday. Pfizer Inc. has a 1 year low of $25.26 and a 1 year high of $41.33. The firm has a fifty day moving average price of $27.19 and a 200 day moving average price of $28.76. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $143.86 billion, a PE ratio of 70.57, a P/E/G ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 EPS. Analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.